Last updated: September 7, 2026
Bisoprolol fumarate/hydrochlorothiazide is a mature fixed-dose combination for hypertension. The commercial opportunity is primarily in reliable generic supply, differentiated tablet performance, patient-friendly formulations, and geographic expansion rather than new-molecule exclusivity. The core formulation challenge is achieving content uniformity for low-dose hydrochlorothiazide, consistent dissolution for both actives, and adequate tablet robustness without increasing manufacturing cost.
What is the regulatory status of bisoprolol fumarate and hydrochlorothiazide?
Bisoprolol fumarate/hydrochlorothiazide is an immediate-release oral tablet approved for the treatment of hypertension. The reference product is Ziac, originally marketed by Lederle Laboratories and later associated with Merck-related product portfolios. The combination is available in strengths containing a fixed 6.25-mg dose of hydrochlorothiazide with different bisoprolol fumarate doses.
| Product characteristic |
Commercial status |
| Active ingredients |
Bisoprolol fumarate and hydrochlorothiazide |
| Dosage form |
Immediate-release tablet |
| Main indication |
Hypertension |
| Common strengths |
2.5/6.25 mg, 5/6.25 mg, and 10/6.25 mg |
| Regulatory pathway for generics |
ANDA, subject to pharmaceutical equivalence and bioequivalence |
| Reference brand |
Ziac |
| Primary market |
Generic hypertension treatment |
| Prescription status |
Prescription-only medicine in major regulated markets |
The fixed-dose combination reduces pill burden for patients who require both a beta blocker and a thiazide diuretic. The combination is clinically established, but demand is constrained by the availability of low-cost single-ingredient bisoprolol and hydrochlorothiazide products.
FDA labeling identifies the combination as an immediate-release tablet and describes the active ingredients as bisoprolol fumarate, a beta-1 selective adrenergic blocker, and hydrochlorothiazide, a thiazide diuretic. (U.S. Food and Drug Administration, 2011)
What excipients are used in bisoprolol fumarate/hydrochlorothiazide tablets?
Public product labels for bisoprolol fumarate/hydrochlorothiazide tablets identify common oral solid-dose excipients, including lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, and magnesium stearate. Excipients differ by manufacturer, strength, market, and manufacturing site.
| Excipient class |
Typical candidates |
Formulation purpose |
| Diluent |
Lactose monohydrate, microcrystalline cellulose |
Tablet mass, compressibility, dose uniformity |
| Binder |
Povidone, copovidone |
Granule and tablet cohesion |
| Disintegrant |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
Tablet breakup and dissolution |
| Glidant |
Colloidal silicon dioxide |
Powder flow and die filling |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Ejection and tooling protection |
| Coating system |
Hypromellose, polyethylene glycol, titanium dioxide, iron oxides |
Appearance, swallowability, identification |
| Colorant |
Iron oxides or permitted lake colors |
Strength differentiation and product identification |
The most commercially important excipient decision is usually the diluent-disintegrant system. Lactose and microcrystalline cellulose provide different compression, moisture, and dissolution profiles. Crospovidone can support rapid disintegration without substantial swelling, while croscarmellose sodium and sodium starch glycolate may produce different water uptake and tablet expansion behavior.
A formulation should not be copied solely from a reference label. The listed excipients establish a regulatory and patient-safety benchmark, but the generic manufacturer can select a different composition if the product meets applicable quality, equivalence, and labeling requirements.
How should the excipient strategy address low-dose hydrochlorothiazide?
The 6.25-mg hydrochlorothiazide dose creates a content-uniformity risk. Hydrochlorothiazide represents a relatively small fraction of total tablet mass, particularly in the 2.5/6.25-mg strength. Segregation, poor blend homogeneity, and differences in particle size can cause potency variability.
A robust strategy should include:
- Controlled active-ingredient particle-size distributions.
- Geometric dilution or ordered blending for low-dose hydrochlorothiazide.
- Excipient grades selected for consistent bulk density and flow.
- Blend uniformity controls near the validated commercial batch scale.
- Compression monitoring for tablet weight, hardness, thickness, and friability.
- Dissolution testing for both active ingredients rather than relying on a single composite endpoint.
Microcrystalline cellulose is useful where the blend requires improved compactability. Lactose can improve tablet mass and mouthfeel but may increase sensitivity to moisture and Maillard-type compatibility concerns with certain amine-containing substances. The compatibility profile should be confirmed through stressed stability studies rather than inferred from excipient history.
Which excipients are most commercially attractive?
Lactose and microcrystalline cellulose
A lactose-cellulose combination is commercially attractive because it supports conventional direct compression or low-shear granulation and is broadly available from global suppliers. It also provides flexibility across the three principal dosage strengths.
Potential risks include:
- Lactose intolerance or patient preference concerns.
- Moisture-related changes in tablet hardness.
- Variability between lactose grades.
- Supply disruption if the product depends on a single qualified grade.
A lactose-free version using microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed excipient could support institutional tenders and selected export markets.
Crospovidone
Crospovidone is suitable where rapid tablet breakup and a relatively low risk of gel formation are priorities. It is often compatible with direct compression and can help maintain dissolution after moderate compression-force changes.
The main commercial limitation is cost relative to some starch-based disintegrants. A manufacturer may use crospovidone in a premium or technically robust formulation while using croscarmellose sodium or sodium starch glycolate in a cost-optimized product.
Povidone and copovidone
Povidone can improve cohesion in granulated systems and reduce friability. It can also affect granule density and dissolution. Excessive binder concentration may delay disintegration, particularly in a small immediate-release tablet.
Copovidone can provide alternative binding and film-forming performance, but it may increase formulation complexity and qualification requirements without creating a strong market advantage.
Magnesium stearate and sodium stearyl fumarate
Magnesium stearate is the standard low-cost lubricant. Over-lubrication can reduce tablet tensile strength and slow wetting or dissolution. Lubrication time, concentration, and blending energy should be controlled as critical process parameters.
Sodium stearyl fumarate can be considered where reduced hydrophobicity or a different compression profile is needed. Its higher cost makes it more appropriate for a differentiated formulation than for a lowest-cost tender product.
What formulations are protected or differentiated by excipient selection?
The basic immediate-release tablet is unlikely to support durable commercial differentiation through excipient choice alone. The stronger opportunities are formulation improvements that solve specific manufacturing or patient-use problems.
Lactose-free tablets
A lactose-free product can target patients with lactose sensitivity and markets where excipient declarations influence prescribing or pharmacy substitution. The opportunity is commercially meaningful only if the product maintains competitive cost and does not require an expensive wet-granulation process.
Small, swallowable tablets
The active-load profile permits a relatively small tablet. A formulation using high-functionality microcrystalline cellulose, co-processed excipients, or optimized roller compaction can reduce tablet size. This may improve adherence, particularly for older patients receiving multiple medicines.
Moisture-resistant tablets
A moisture-controlled formulation can use low-moisture excipient grades, protective film coating, high-barrier packaging, and desiccant-enabled bottles. This is relevant where distribution occurs in hot and humid climates. Stability improvement can reduce product loss and expand export opportunities.
Color-coded strength platforms
Using a common excipient platform with strength-specific colorants can reduce manufacturing complexity while lowering medication-error risk. The three principal strengths can use distinct colors, debossing, or shape differences. Any differentiation must comply with local labeling and appearance requirements.
Sprinkle or orally disintegrating formats
These formats offer a higher-value opportunity but require substantial development. Bisoprolol fumarate/hydrochlorothiazide is normally supplied as a conventional tablet. An orally disintegrating tablet or sprinkle formulation would need to address taste, dose uniformity, moisture sensitivity, and stability. The fixed 6.25-mg hydrochlorothiazide component may limit the commercial value of pediatric or dysphagia-focused presentations because the combination is primarily used in adults.
How does excipient choice affect manufacturing economics?
The lowest-cost route is generally direct compression if both active ingredients and excipients have suitable flow and compactability. Direct compression reduces equipment, solvent, drying, and cycle-time requirements.
| Manufacturing route |
Cost profile |
Main benefit |
Main risk |
| Direct compression |
Lowest |
Simple process and high throughput |
Blend segregation and content uniformity |
| Dry granulation |
Moderate |
Improves flow and density without water |
Roller-compaction variability |
| Wet granulation |
Highest |
Strong granules and improved uniformity |
Drying burden, moisture exposure, longer cycle |
| Co-processed excipient platform |
Moderate to high |
Simplifies development and improves robustness |
Higher excipient cost and supplier dependence |
For the 2.5/6.25-mg strength, dry granulation or a controlled premix may provide better uniformity than a simple direct-compression blend. For higher bisoprolol strengths, direct compression may be easier because the active-to-excipient ratio is more favorable.
Commercial development should evaluate the total cost of ownership, including:
- Excipient price.
- Yield loss.
- Compression speed.
- Tablet rejection rate.
- Stability failures.
- Packaging requirements.
- Analytical testing burden.
- Supplier qualification.
- Change-control costs.
A more expensive disintegrant can be economically justified if it permits faster compression, fewer dissolution failures, or a common process across all strengths.
What generic entry opportunities exist?
The combination has a mature generic profile and limited conventional product differentiation. Commercial entry opportunities include:
United States ANDA supply
An ANDA applicant can compete through price, manufacturing reliability, wholesaler coverage, and a complete strength portfolio. FDA requirements include pharmaceutical equivalence, bioequivalence, chemistry and manufacturing controls, stability data, and appropriate labeling.
The product is an immediate-release solid oral combination, so the principal development risks are formulation performance, blend uniformity, dissolution, and scale-up rather than complex delivery technology.
Regional and emerging markets
Demand may be stronger in markets where fixed-dose combinations are favored for adherence or where local hypertension guidelines support combination therapy. A manufacturer with local registration, government-tender capability, and reliable supply can compete even without a novel formulation.
The most useful geographic formulation adaptations include:
- Moisture-resistant packaging for tropical climates.
- Lactose-free excipient systems where required by local practice.
- Multilingual labeling and strength-specific color coding.
- Blister packs for adherence and institutional distribution.
- Bottles for lower unit cost in high-volume markets.
Contract manufacturing and licensing
The product is suitable for contract development and manufacturing organizations with established immediate-release tablet capacity. Licensing value is usually linked to registration status, territory, supply reliability, and manufacturing cost rather than to proprietary excipient technology.
A differentiated deal could package:
- U.S. or European regulatory approval.
- Multiple strengths.
- Drug-master-file support for excipients or manufacturing.
- Dual-site supply.
- Local commercialization rights.
- A lactose-free or climate-stable formulation.
What is the Orange Book and patent status of bisoprolol fumarate/hydrochlorothiazide?
The key U.S. reference product is Ziac. The combination is a mature product with generic competition, and the principal commercial barriers are regulatory execution, manufacturing economics, and channel access rather than new-chemical-entity exclusivity.
| IP issue |
Commercial assessment |
| Original active-ingredient exclusivity |
Expired for a mature combination product |
| Current generic pathway |
ANDA |
| Paragraph IV opportunity |
Limited value unless a current listed patent remains relevant |
| Formulation patents |
Potentially relevant only if an unexpired, claim-scope-specific patent exists |
| Method-of-use patents |
Generally weak for a long-established hypertension indication |
| Manufacturing patents |
Possible for specific processes, polymorphs, or particle-size controls |
| Biosimilar risk |
Not applicable; this is a conventional small-molecule product |
| Primary entry risk |
Bioequivalence, content uniformity, stability, supply, and price erosion |
Current patent and Orange Book status must be assessed against the applicable FDA Orange Book edition and patent-listing records before filing or launch. Patent expiration dates can vary by patent family, terminal disclaimers, pediatric extensions, and listing corrections. The commercial case should not rely on historical Ziac patent data without confirming the active listing record. (U.S. Food and Drug Administration, 2024)
Which companies are challenging or competing with the reference product?
The market is populated by generic manufacturers rather than biosimilar developers. Competition can come from:
- Large multinational generic companies.
- Regional antihypertensive manufacturers.
- Contract manufacturers supplying private-label products.
- Companies offering bisoprolol or hydrochlorothiazide separately.
- Manufacturers competing through pharmacy and government tenders.
The most direct competitive threat is substitution with separate tablets. A fixed-dose combination must offset the price advantage of separate generic components through adherence, convenience, formulary positioning, or lower total dispensing cost.
How strong is the commercial patent estate?
The patent estate is weak as a platform for long-term exclusivity because the product is an established small-molecule combination with conventional immediate-release delivery. New patent value could arise from a narrowly claimed:
- Polymorph or salt form.
- Particle-size distribution.
- Manufacturing process.
- Stability-improving excipient system.
- Modified-release or abuse-deterrent presentation.
- Specific patient population or dosing regimen.
Such claims would require a clear technical effect and would face obviousness and enablement scrutiny. A broad claim covering routine excipient substitution would likely provide limited protection.
What litigation and settlement risks affect generic launch?
The principal litigation risk is a patent challenge if a currently listed patent covers the product or a claimed method of use. For a mature combination, litigation exposure is typically lower than for recently approved branded drugs, but it is not zero.
Generic launch planning should evaluate:
- Paragraph IV certifications.
- Thirty-month stays under the Hatch-Waxman framework.
- ANDA first-filer status.
- Settlement restrictions.
- Authorized-generic arrangements.
- Product-label carve-outs for method-of-use claims.
- Risk of supply interruption from manufacturing litigation.
A formulation applicant should separate patent freedom-to-operate analysis from FDA substitutability. FDA approval does not eliminate patent infringement risk, and an apparently non-infringing excipient change does not resolve claims directed to active ingredients, dosage forms, or manufacturing methods.
What revenue exposure and market opportunities exist?
Bisoprolol fumarate/hydrochlorothiazide is unlikely to support the revenue profile of a protected branded drug. Its value is volume-based.
Revenue opportunities are strongest where a company can combine:
- Low-cost, high-yield tablet production.
- Complete strength coverage.
- Consistent national supply.
- Tender eligibility.
- Private-label distribution.
- Differentiated excipient claims that solve a real patient or manufacturing problem.
A product launch can be structured in tiers:
| Tier |
Product proposition |
Target buyer |
| Economy |
Conventional lactose-based generic |
Retail pharmacy and tenders |
| Standard |
Robust three-strength platform with coated tablets |
National generic market |
| Differentiated |
Lactose-free or moisture-resistant formulation |
Selected prescribers and export markets |
| Premium |
Small tablet, adherence-oriented packaging, dual-site supply |
Managed care and institutional buyers |
The principal risk is rapid price erosion after multiple ANDA approvals. A manufacturer should avoid a high-cost excipient system unless it supports a defensible regulatory, supply, or marketing advantage.
Key Takeaways
- Bisoprolol fumarate/hydrochlorothiazide is a mature immediate-release fixed-dose combination with generic-market economics.
- The critical formulation issue is low-dose hydrochlorothiazide uniformity, especially in the 2.5/6.25-mg strength.
- Lactose, microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, and magnesium stearate are commercially practical excipient choices.
- Direct compression is attractive, but dry granulation may improve blend uniformity and flow for low-dose presentations.
- Lactose-free, moisture-resistant, small-tablet, and color-coded strength platforms offer the most credible differentiation.
- Biosimilar risk does not apply because the product contains conventional small-molecule active ingredients.
- The patent estate is unlikely to create durable broad exclusivity; current Orange Book and patent records remain essential for launch timing.
- Commercial success depends on manufacturing yield, complete strength coverage, geographic registration, tender access, and supply reliability.
FAQs
Is bisoprolol fumarate/hydrochlorothiazide a biosimilar product?
No. It is a conventional small-molecule fixed-dose combination. Generic versions are approved through the ANDA or equivalent national generic pathway, not through a biosimilar pathway.
Can a lactose-free bisoprolol/hydrochlorothiazide tablet be commercially differentiated?
Yes. A lactose-free tablet can address excipient preferences and selected patient populations, but it must maintain equivalent quality, dissolution, stability, and bioequivalence while remaining cost competitive.
Which excipient is best for hydrochlorothiazide content uniformity?
No single excipient guarantees uniformity. A controlled premix, compatible diluent system, appropriate particle-size control, and validated blending process are more important than the choice of any individual diluent.
Is an orally disintegrating bisoprolol/hydrochlorothiazide tablet commercially attractive?
It is technically possible but commercially uncertain. Taste masking, moisture protection, low-dose uniformity, and the limited size of the dysphagia-focused market would need to justify the added development cost.
What is the main generic launch risk for this combination?
The main risks are failed content-uniformity or dissolution results, scale-up variability, price erosion, and inability to secure reliable supply across all marketed strengths.
References
-
U.S. Food and Drug Administration. (2011). ZIAC- bisoprolol fumarate and hydrochlorothiazide tablet, film coated: Prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2022). Guidance for industry: Immediate release solid oral dosage forms scale-up and postapproval changes. U.S. Department of Health and Human Services.
-
World Health Organization. (2016). WHO expert committee on specifications for pharmaceutical preparations: Fifty-first report. World Health Organization.
